---
schema_version: "secwatch.filing_event.v1"
accession: "0001906324-23-000030"
form_type: "8-K"
ticker: "QDEL"
cik: "0001906324"
company_name: "QuidelOrtho Corp"
filed_at: "2023-05-03T23:59:59+00:00"
generated_at: "2026-06-16T01:44:15.237400+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Q1 revenue $846.1M, down 16%; GAAP EPS $0.73, adjusted EPS $1.80

## Summary
- Total revenue $846.1M, down 16% YoY; non-respiratory up 5% on supplemental combined basis.
- GAAP EPS $0.73 vs $11.31; adjusted EPS $1.80 vs $8.03 on combined basis, down 78%.
- Labs business drove non-respiratory growth with double-digit growth; respiratory revenue down 72%.
- Adjusted EBITDA $245.3M (29% margin) vs $780.8M (52% margin) in prior year.
- Integration on track; guidance to be provided on conference call; expects sustainable high-single-digit growth.

## SEC filing metadata
- accession: 0001906324-23-000030
- form_type: 8-K
- ticker: QDEL
- cik: 0001906324
- company_name: QuidelOrtho Corp
- filed_at: 2023-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1906324/000190632423000030/0001906324-23-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1906324/000190632423000030/qdel-20230503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001906324-23-000030
- JSON: https://secwatch.observer/filing/0001906324-23-000030.json
- Plain text: https://secwatch.observer/filing/0001906324-23-000030.txt

## Key facts
- Earnings Releases
  QuidelOrtho Corp reported first quarter ended April 2, 2023 results: revenue $846.1 million, EPS $0.73.
  - Period: first quarter ended April 2, 2023
  - Revenue: $846.1 million
  - EPS: $0.73
  - Result: reported results
  source text: any general incorporation language in such filing. --- EX-99.1 (EX-99.1) --- QuidelOrtho Reports First Quarter 2023 Financial Results Highligh ts • First quarter revenue of $846.1 million decreased by 16% as reported with non-respiratory revenue up 5% on a supplemental combined basis (up 7% in constant currency) and respiratory revenue down 72% on a supplemental
  evidence_url: https://www.sec.gov/Archives/edgar/data/1906324/000190632423000030/0001906324-23-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.